Here’s the version of predictive modelling in pharma that doesn’t get discussed enough in vendor conversations: the one where the
Outcome Prediction Models in Healthcare: Using RWD to Build Predictive Analytics Read Post »
Here’s a pattern we see repeatedly in the RWE programmes we advise on across Continental European markets: a company selects
Longitudinal Data Analysis in Pharma: What Makes a Dataset Fit for Purpose Read Post »
Most RWE teams in pharma are fluent in US claims logic. They know Optum. They know IBM MarketScan. They know
In December 2025, the FDA announced it was eliminating a major barrier to using real-world evidence in drug and device
Here’s a scenario that will feel uncomfortably familiar to anyone who has tried to initiate a real-world data programme inside
Here’s the assumption that gets small and mid-size pharma companies into trouble more often than any other: that real-world evidence
Every year, pharma companies spend tens of millions of dollars on real-world evidence programmes that fail to deliver what was
Here’s a number that should make any launch team uncomfortable: more than half of all pharma launches miss their commercial
Here’s a conversation I have more often than you’d think. A VP of Market Access — smart, experienced, absolutely knows
You’re the Head of Market Access at a 200-person specialty biotech. Your lead asset is 18 months from a potential
